Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results

Abstract Introduction Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on oral medications. We present the first multicountry real-world data from routine clinical practi...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Wolfgang H. Jost, Filip Bergquist, Andrew Evans, Sharon Hassin-Baer, Robert A. Hauser, Tove Henriksen, Irene A. Malaty, Tiago A. Mestre, Pablo Mir, Ramon Rodriguez, Petra Schwingenschuh, Mihaela Simu, Lars Bergmann, Teresa T. Zhou, Sarah Caughlin, Mallika Gopalkrishnan, Pavnit Kukreja, Marie O’Meara, Juan Carlos Parra, Megha B. Shah, Jason Aldred
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2026-05-01
Serie:	Neurology and Therapy
Soggetti:	Carbidopa Foslevodopa Foscarbidopa Levodopa Parkinson’s disease Real-world evidence
Accesso online:	https://doi.org/10.1007/s40120-026-00948-6
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!